ASCO 2025 | Triplet therapy improves PFS in melanoma brain metastases in SWOG S2000
Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, comments on the Phase II SWOG S2000 trial (NCT04511013) of encorafenib, binimetinib, with nivolumab versus ipilimumab and nivolumab in patients with symptomatic BRAFV600-mutant melanoma brain metastases. The triplet regimen demonstrated improved progression-free survival compared to the immunotherapy doublet, meeting the primary endpoint. Response rates were higher with the triplet approach, with toxicity profiles consistent with prior studies. These findings suggest a potential role for targeted plus immunotherapy in this challenging patient population. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
